Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma

Yan Wang1, Peng Zhao1, Lili Wang1

  • 1Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Abstract

Insights

This study identifies ELOC(TCEB1)-mutant renal cell carcinoma (RCC) as a rare cancer primarily affecting middle-aged men. These tumors often show specific structural and molecular features, and typically have an inert clinical behavior.

Area of Science:

  • Urology
  • Oncology
  • Molecular Pathology

Background:

  • Renal cell carcinoma (RCC) encompasses diverse subtypes with varying clinical behaviors.
  • Identifying novel genetic drivers and their associated clinicopathological features is crucial for accurate diagnosis and management.
  • ELOC(TCEB1) mutations represent a rare but distinct molecular subtype of RCC.

Purpose of the Study:

  • To investigate the clinicopathological and molecular characteristics of ELOC(TCEB1)-mutant renal cell carcinoma.
  • To identify diagnostic markers and understand the clinical behavior of this rare RCC subtype.

Main Methods:

  • Sanger sequencing was employed to screen 32 cases of clear cell RCC with specific histological features.
  • Four patients with confirmed ELOC(TCEB1) gene mutations underwent detailed clinicopathological analysis.
  • Histomorphological observation, immunohistochemical staining, and literature review were performed.

Main Results:

  • The 4 identified patients were males aged 57-64 years, with tumors located in the renal cortex.
  • Histological findings included branching alveolar/tubular structures, fibromyomatous stroma, and positive expression of EMA, CA9, AMACR, and nuclear TCEB1.
  • All patients had the ELOC(TCEB1) Y79C mutation, showed low nuclear grade, and had no recurrence or metastasis during a mean 49-month follow-up.

Conclusions:

  • ELOC(TCEB1)-mutant RCC is a rare entity in middle-aged to elderly men, characterized by specific histological and molecular profiles.
  • Positive TCEB1 nuclear staining and expression of CK7, CA9, CD10, and AMACR are key diagnostic indicators.
  • This subtype generally exhibits an inert clinical behavior with a favorable prognosis, though some cases may present aggressive characteristics.